Questioning the Association of the STMN2 Dinucleotide Repeat With Amyotrophic Lateral Sclerosis. (13th August 2022)

• Record Type: Journal Article
• Authors: Ross, Jay P.; Akçimen, Fulya; Liao, Calwing; Spiegelman, Dan; Weisburd, Ben; Dupré, Nicolas; Dion, Patrick A.; Rouleau, Guy A.; Farhan, Sali M.K.
• Is Part Of: Neurology. Volume 8:Number 4(2022)
• Publication Date: 2022-08-13
• Subjects: Neurogenetics -- Periodicals; 616.80442
• DOI: 10.1212/NXG.0000000000000678
• Languages: English
• ISSNs: 2376-7839

Abstract

Abstract : Objectives: Recently, the number of dinucleotide CA repeats in an intron of the STMN2 gene was reported to be associated with an increased risk for amyotrophic lateral sclerosis (ALS). Therefore, we sought to replicate this observation in an independent group of ALS patients and a much larger control group. Methods: Here, we used whole-genome sequencing and tested the STMN2 CA repeat in a case-control cohort of the European genetic background and in genomes from various populations in the gnomAD cohort to attempt to replicate this proposed association. Results: We find that repeats well above the previously reported pathogenic threshold of 19 are commonly observed in unaffected individuals across different populations. Furthermore, we did not observe an association between longer STMN2 CA repeats and ALS phenotype. Discussion: In summary, our results do not support a role of STMN2 CA repeats toward ALS risk. As TDP-43 aggregation is central to ALS pathogenesis, lowered expression of STMN2 could be used as a biomarker for ALS. Therefore, a variant associated both with the risk for ALS and the level of STMN2 expression would be clinically useful. However, for a variant to be actionable, it must be strongly replicated in independent cohorts and exceed the rigorous statistical thresholds applied.